BALCAO · MISCELLANEOUS CHEMICAL PRODUCTS · SMALL CAP
Pure Bioscience, Inc. PURE
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.2M
▲ 12.2% vs FY2024
EPS · FY25
$-0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-108.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.2M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 109 cents on every revenue dollar this year.
Per share
USD -0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-103.2%
Net margin-108.9%
Return on assets-255.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−20.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.9%
−20.5%
+11.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+28.5%
Change, 10 years—
The share count grew 28% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1M
total assets, end of FY2025
Total assetsUSD 1.1M
EquityUSD -5.1M
CashUSD 334,000.00
Gross debtUSD 5.2M
Net debtUSD 4.9M
Current ratio1.12×
Net debt stands at -96% of equity.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.02
−0.03
−0.04
−0.04
−0.03
0.00
−0.09
−0.11
−0.10
−0.25
−0.19
−0.43
−0.71
−1.58
−1.79
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−189.5
−96.4
−56.9
0.1
−530.5
−578.9
−198.4
−388.1
−635.6
·
·
−353.8
−198.5
Shares out B
0.11
0.11
0.11
0.11
0.09
0.09
0.08
0.07
0.06
0.06
0.04
0.03
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed